Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar. CRISPR Therapeutics has an approved gene-editing ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

Prosper Junior Bakiny has positions in Alphabet, Amazon, and Vertex Pharmaceuticals. The Motley Fool has positions in and ...

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

Amazon ($AMZN) has come out on top of rivals such as Nvidia ($NVDA) when it comes to utilizing AI to fight diseases. However, ...

Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns ...

Trying to figure out what to do with Intellia Therapeutics stock? You’re definitely not alone. After all, this is a company that’s been on quite the rollercoaster lately. Over just the past week, ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...